Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Blood (2019) 134 (Supplement_1): 695.

https://doi.org/10.1182/blood-2019-121694

Published: 2019

Journal Articles

Predictors of Febrile Neutropenia Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice

Gary H. Lyman, MD MPH, Kathryn Richert-Boe, MD MPH, Lois Lamerato, PhD, Manpreet Kaur, MPH, MBA, Neel Shah, BPharm, PhD, Tatiana Lawrence, MD, Devi Sundaresan, MS, Amanda Silvia, BS, Ahuva Hanau, BS, Derek Weycker, PhD

Blood (2019) 134 (Supplement_1): 5854.

https://doi.org/10.1182/blood-2019-123524

Published: 2019

Journal Articles

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Taiga Nishihori, MD, Rachid Baz, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Frederick L. Locke, MD, Jongphil Kim, PhD, Jinming Song, MD PhD, Michael Dumala, Melissa Alsina, MD

Blood (2019) 134 (Supplement_1): 3189.

https://doi.org/10.1182/blood-2019-131451

Published: 2019

Journal Articles

Analysis of Micro-RNAs Associated to Treatment Failure in Diffuse Large B Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1627.

https://doi.org/10.1182/blood-2019-130544

Published: 2019

Journal Articles

Factors Relating to the Favorable Outcome in Reduced-Dose R-CHOP Therapy for Elderly DLBCL Patients

Keiko Ono, MD, Hideki Tsujimura, MD PhD, Satoshi Maruyama, MD, Akiyasu Satou, MD, Takeaki Sugawara, MD PhD, Kyoya Kumagai, MD

Blood (2018) 132 (Supplement 1): 4241.

https://doi.org/10.1182/blood-2018-99-110699

Published: 2018

Journal Articles

Impact of Total Dose Intensity and Relative Dose Intensity (RDI) of R-CHOP on Survival in Patients with DLBCL

Ayumi Komuro, Sachiko Seo, MD PhD, Nobuo Mochizuki, Yosuke Minami, MD PhD, Toshikatu Kawasaki

Blood (2018) 132 (Supplement 1): 4218.

https://doi.org/10.1182/blood-2018-99-114227

Published: 2018

Journal Articles

Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study

Blood (2018) 132 (Supplement 1): 782.

https://doi.org/10.1182/blood-2018-99-118519

Published: 2018

Journal Articles

Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival

Blood (2018) 132 (Supplement 1): 572.

https://doi.org/10.1182/blood-2018-99-111901

Published: 2018

Journal Articles

Impact of Intended and Relative Dose Intensity of RCHOP in a Large, Consecutive Cohort of Elderly DLBCL Patients: No Difference in DFS for 70-80 Years Versus >80 Years and Idi Independently Predicts Survival

Toby A. Eyre, Nicolas Martinez-Calle, MD, Catherine Hildyard, David W. Eyre, Hannah Plaschkes, Jonathan Griffith, Julia Wolf, Chris P Fox, Andrew McMillan, Mark Bishton, Graham P. Collins, MB BS DPhil, Chris Hatton, MD

Blood (2018) 132 (Supplement 1): 573.

https://doi.org/10.1182/blood-2018-99-110330

Published: 2018

Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, PhD, Mark-David Levin, MDPhD, Noortje Thielen, MD PhD, Saskia K. Klein, MD PhD, Inge Ludwig, MD MSc, Matthijs Westerman, MD, Paula F Ypma, MDPhD, Yavuz Bilgin, MDPhD, Maaike Sohne, MD, Esther de Waal, PhD, Niels WCJ van de Donk, MD PhD, Pieter Sonneveld, MDPhD, Sonja Zweegman, MDPhD

Blood (2018) 132 (Supplement 1): 596.

https://doi.org/10.1182/blood-2018-99-114668

Published: 2018

Journal Articles

Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen

Robert M Rifkin, MD, Ralph V. Boccia, MD, Suman Kambhampati, MD, Joshua R Richter, MD, Saad Z Usmani, MD, Jack Aiello, EE, MS, BS, Brittany Sickler, BA, BS, Magdalena Schoeneich, MBA, MS, Bingxia Wang, PhD, Susan Zelt, PhD, Presley Whidden, MS, Lawrence E Dollar, PharmD, MS, Liviu Niculescu, MD, Stephen J Noga, MD

Blood (2017) 130 (Supplement 1): 5407.

https://doi.org/10.1182/blood.V130.Suppl_1.5407.5407

Published: 2017

Journal Articles

Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study

Andrei Shustov, MD, Patrick B Johnston, MD PhD, Stefan Klaus Barta, MDMRCP,MS, Gajanan Bhat, Guru Reddy, Yasuhiro Oki, MD

Blood (2017) 130 (Supplement 1): 818.

https://doi.org/10.1182/blood.V130.Suppl_1.818.818

Published: 2017

Journal Articles

Granulocyte Colony-Stimulating Factor (GCSF) Use with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone +/- Rituximab (CHOP±R) Treatment for Aggressive Non-Hodgkin's Lymphoma (aNHL)

Tom Kouroukis, MD, Winson Y. Cheung, Nizar Abdel-Samad, Sandeep Sehdev, Melanie Poulin-Costello, Brad Gillesby, Ewan J.D. Robson

Blood (2016) 128 (22): 3038.

https://doi.org/10.1182/blood.V128.22.3038.3038

Published: 2016

Journal Articles

Retrospective Study of the Optimal CHOP Dose for Elderly Patients with Diffuse Large B-Cell Lymphoma

Keiko Ono, MD, Hideki Tsujimura, MD, Akiyasu Satou, MD, Xiaofei Wang, MD PhD, Takeaki Sugawara, MD PhD, Mikiko Ise, MD PhD, Kyoya Kumagai, MD

Blood (2016) 128 (22): 4211.

https://doi.org/10.1182/blood.V128.22.4211.4211

Published: 2016

Journal Articles

Red Cell Distribution Width (RDW) at Diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL) Is Associated to Higher Mortality and Worse Overall Survival

Leyre Bento, MD, Juan Sarmentero, MD, Ana Ortuño, MD, Marta García-Recio, MD, Bernardo Lopez, Jordi Martínez-Serra, PhD, Jose Rodriguez, MD PhD, Antonia Sampol, Antonio Gutierrez, MD PhD

Blood (2016) 128 (22): 5398.

https://doi.org/10.1182/blood.V128.22.5398.5398

Published: 2016

Journal Articles

Multicenter, Open-Label Phase I Clinical Study of Oral Rigosertib in Japanese Patients with Recurrent/Relapsed or Refractory Myelodysplastic Syndromes: Tolerability, Efficacy, and Pharmacokinetic Profiles

Kenichi Ishizawa, MD PhD, Kensuke Usuki, MD PhD, Kiyoshi Ando, MD PhD, Yasunori Ueda, MD PhD, Toru Kiguchi, MD PhD, Naokuni Uike, MD PhD, Yasushi Onishi, MD PhD, Hiroatsu Iida, MD PhD

Blood (2016) 128 (22): 5538.

https://doi.org/10.1182/blood.V128.22.5538.5538

Published: 2016

Journal Articles

Safety, Efficacy, and Pharmacokinetic Profiles of Intravenous Rigosertib in Japanese Patients with Recurrent/Relapsed or Refractory Myelodysplastic Syndromes: A Multicenter, Open-Label Phase I Clinical Study

Michinori Ogura, Yukio Kobayashi, MD PhD, Shiro Kubonishi, MD PhD, Michihiro Hidaka, MD PhD, Toshiki Uchida, MD PhD, Yasushi Takamatsu, MD PhD

Blood (2016) 128 (22): 5549.

https://doi.org/10.1182/blood.V128.22.5549.5549

Published: 2016

Journal Articles

OPEC/Mpec for Adult T-Cell Leukemia/Lymphoma: A Single-Institution Study

Daisuke Nakamura, MD, PhD, Makoto Yoshimitsu, MD, PhD, Tomohisa Tabuchi, MD, Naosuke Arima, MD, Maiko Hayashida, MD, Hirosaka Inoue, MD, Kakushi Matsushita, MD, PhD, Tadashi Matsumoto, MD, PhD, Naomichi Arima, MD, PhD, Kenji Ishitsuka, MD, PhD

Blood (2016) 128 (22): 1828.

https://doi.org/10.1182/blood.V128.22.1828.1828

Published: 2016

Journal Articles

A New Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Blood (2015) 126 (23): 2680.

https://doi.org/10.1182/blood.V126.23.2680.2680

Published: 2015

Journal Articles

Chemotherapy Relative Dose Intensity and Therapy Efficacy in Hodgkin and Non-Hodgkin Lymphoma: The Effect of Dose Reductions and Delays on Cure

Elizabeth Bowhay-Carnes, MD, Christos Fountzilas, MD, Michelle Janania Martinez, MD, Brandon Konkel, MD, Brandon Stormes, Anand Karnad, MD

Blood (2015) 126 (23): 5092.

https://doi.org/10.1182/blood.V126.23.5092.5092

Published: 2015

NARROW

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Predictors of Febrile Neutropenia Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Analysis of Micro-RNAs Associated to Treatment Failure in Diffuse Large B Cell Lymphoma

Factors Relating to the Favorable Outcome in Reduced-Dose R-CHOP Therapy for Elderly DLBCL Patients

Impact of Total Dose Intensity and Relative Dose Intensity (RDI) of R-CHOP on Survival in Patients with DLBCL

Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study

Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival

Impact of Intended and Relative Dose Intensity of RCHOP in a Large, Consecutive Cohort of Elderly DLBCL Patients: No Difference in DFS for 70-80 Years Versus >80 Years and Idi Independently Predicts Survival

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study

Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen

Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study

Granulocyte Colony-Stimulating Factor (GCSF) Use with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone +/- Rituximab (CHOP±R) Treatment for Aggressive Non-Hodgkin's Lymphoma (aNHL)

Retrospective Study of the Optimal CHOP Dose for Elderly Patients with Diffuse Large B-Cell Lymphoma

Red Cell Distribution Width (RDW) at Diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL) Is Associated to Higher Mortality and Worse Overall Survival

Multicenter, Open-Label Phase I Clinical Study of Oral Rigosertib in Japanese Patients with Recurrent/Relapsed or Refractory Myelodysplastic Syndromes: Tolerability, Efficacy, and Pharmacokinetic Profiles

Safety, Efficacy, and Pharmacokinetic Profiles of Intravenous Rigosertib in Japanese Patients with Recurrent/Relapsed or Refractory Myelodysplastic Syndromes: A Multicenter, Open-Label Phase I Clinical Study

OPEC/Mpec for Adult T-Cell Leukemia/Lymphoma: A Single-Institution Study

A New Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Chemotherapy Relative Dose Intensity and Therapy Efficacy in Hodgkin and Non-Hodgkin Lymphoma: The Effect of Dose Reductions and Delays on Cure

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only